RNA Analysis Market, with a 12.45% CAGR, is projected to increase from USD 5.572 billion in 2025 to USD 11.269 billion in 2031.
RNA analysis is a broad term that encompasses various techniques and methods used to study RNA molecules within a biological sample. RNA (ribonucleic acid) is a fundamental molecule involved in gene expression, protein synthesis, and regulation of cellular processes. The rising incidence of cancer and infectious diseases and the valuable application of RNA analysis in these diseases is a major growth driver of the RNA analysis market. Moreover, the increasing adoption of personalized medication along with the numerous research studies and developments to improve the RNA-based solutions are further accelerating the RNA analysis market growth.
Rising Prevalence of Cancer
RNA analysis has played a significant role in advancing cancer research and understanding the molecular mechanisms underlying cancer development and progression. The rising cancer cases are therefore a major growth driver of the RNA analysis market. For instance, cancer is the major leading cause of death worldwide which amounted to 10 million deaths in 2020 as per the WHO. According to the World Cancer Research Fund, there were an estimated 18.1 million new cancer cases worldwide. There were 8.8 million cases in women and 9.3 million in males. RNA analysis, especially through RNA-sequencing has been crucial in the discovery of novel fusion genes and understanding their role in various cancer types.
Growing Burden of Infectious Diseases
The RNA analysis market is widening due to the rising number of infectious diseases around the globe. The study of RNA in infectious disease research provides valuable information about the genetic makeup of pathogens, their virulence factors, and how they interact with the host immune system. For instance, around 39 million people were living with HIV worldwide in 2022 as per the WHO data. HIV-related deaths accounted for 630,000 deaths in 2022, and 1.3 million persons contracted the virus. Further, over 265,159 samples were evaluated by the WHO GISRS laboratories throughout the two weeks in June 2023.
Increasing Emphasis on Personalized Medicine
The study of RNA in cancer research has allowed for the identification of cancer-specific gene expression patterns and potential biomarkers for early diagnosis and personalized treatment. There are numerous ongoing research to develop more targeted treatments for the treatment of cancer using RNA which is expected to boost the RNA analysis market. For example, Moderna Inc. and Merck announced that the U.S. Food and Drug Administration (FDA) had designated mRNA-4157/V940 investigational personalized mRNA cancer vaccine as a breakthrough therapy for the adjuvant treatment of patients with high-risk melanoma after complete resection.
Biopharmaceutical Research and Development
In the pharmaceutical industry, RNA analysis is crucial for drug discovery, target identification, and biomarker research. The increasing development of RNA-based therapeutics, such as mRNA vaccines and RNA interference (RNAi) therapies is also driving the RNA analysis market. For instance, between 2010 and 2019, there was a 60 percent increase in the number of new drugs approved for sale compared to the previous decade in the US according to the Congressional Budget Office. The AlphaFold2 AI technology from DeepMind significantly improved human understanding of biology. With that development, Alphabet launched Isomorphic Labs in 2021 which was a brand-new business specializing in AI-driven medication discovery.
Increasing Research and Government Initiative
The increasing research projects and government initiatives for medical study and enhanced treatment using RNA are contemplated to aid the RNA analysis market. For instance, new research by the University of Innsbruck developed a new method to study the binding of aminoglycoside Neomycin B to a so-called mRNA riboswitch in July 2023. Additionally, research by the University of Otago began in July 2023 to improve RNA diagnostics to provide more certainty for genetic testing. It aims to examine how changes to DNA affect a similar molecule RNA. Moreover, the inauguration of the Darlington RNA vaccine innovation facility was supported by an extra Β£10.65 million in funding from the UK government's Vaccine Taskforce in October 2022.
North America is Expected to Grow Significantly
North America is expected to hold a significant share of the RNA analysis market during the forecast period. The factors attributed to such a share are the rising number of cancer cases, infectious diseases, government support, technological advancements, and multiple research studies. For instance, according to National Cancer Institute estimates, around 1.8 million new cases of cancer were identified in the US year 2020 and 606,520 individuals died from the illness. The majority of cancer cases (1,117,640) occurred among adults 65 and older, more than any other age group. The elderly population aged 65 years or above is continuously rising in the region which is further increasing the demand for RNA analysis.
Promega Corporation is a global biotechnology company that specializes in providing innovative solutions for life sciences research, drug discovery, clinical diagnostics, and applied fields. Standalone reverse transcriptases (AMV, M-MLV, and GoScript) and a variety of full kits with enzymes, buffers, and reagents are available as Promega RT-PCR products.
Lexogen was founded in 2007 with a primary focus to provide products and services that enable researchers to study RNA molecules in various biological samples and contexts. It offers CORALL RNA-Seq Library Prep kits, LUTHOR 3β mRNA-Seq Library kits, and several other ranges of RNA products.
Zymo Research Corporation is a US-based biotechnology company. It specializes in providing research tools and services for epigenetics, nucleic acid purification, and microbiomics. It offers a total of 52 RNA-related kits including Direct-zol RNA Microprep kits and Direct-zol-96 RNA kits.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 β 2031 |
| Companies |
|
Report Metric | Details |
RNA Analysis Market Size in 2025 | USD 5.572 billion |
RNA Analysis Market Size in 2030 | USD 10.196 billion |
Growth Rate | CAGR of 12.84% |
Study Period | 2020 to 2030 |
Historical Data | 2020 to 2023 |
Base Year | 2024 |
Forecast Period | 2025 β 2030 |
Forecast Unit (Value) | USD Billion |
Segmentation |
|
Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
List of Major Companies in the RNA Analysis Market |
|
Customization Scope | Free report customization with purchase |
RNA Analysis Market Segmentation
By Type
Messenger RNA (mRNA)
Transfer RNA (tRNA)
Others
By Application
Reagnet
Kits
Enzymes
Others
By End-User
Pharmaceutical & Biotech Companies
Academic & Research Institutes
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others